Amgen

Open: 258.68 Close: 256.71 Change: -1.97

Are you looking for information about Amgen Company Inc? We programmed an AI to summarize it for you.

This document will help you to evaluate Amgen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, FTC, Horizon, Therapeutics, lawsuit, drug, product, and the …

Concept Map

Semantic Network

Stock Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's products include Enbrel, Prolia, Xgeva, Otezla, Aranesp, and Repatha..

Today's Summary

Federal Trade Commission (FTC) has allowed Amgen to continue its $27.8 billion acquisition of Horizon Therapeutics. FTC in May filed a lawsuit over concerns that Amgen would leverage its drugs to secure favorable coverage.

Today's News

Amgen and Horizon Therapeutics have reached a consent order agreement with the Federal Trade Commission (FTC) to resolve an ongoing administrative lawsuit. Amgen reached an agreement to acquire Horizon in December last year. Amgen $27.8 billion deal for horizon therapeutics clears key hurdle - wsj. amgens $27.8 billion Deal for Horizon Therapeutics Clears Key Hurdle. Federal Trade Commission (FTC) has allowed Amgen to continue its $27.8 billion acquisition of Horizon Therapeutics. The agreement ends months of uncertainty over the deal since the FTC in May filed a lawsuit over concerns that Amgen would leverage its drugs to secure favorable insurance coverage. Amgen must seek FTC approval if it seeks to acquire any pre-commercial products that have completed FDA clinical trials to treat either thyroid eye disease or chronic refractory gout. Amgen is barred from using any product rebate or contract term to exclude or disadvantage any product that would compete with Tepezza. Amgen Inc. (amgn) stock price, news, quote & history - yahoo finance.com. Amgen stock rose Friday after the FTC dropped its lawsuit, clearing the way for the biotech to buy Horizon Therapeutics for $28 billion. FTC pauses suit against Amgen on $28B acquisition of Horizon Therapeutics to allow time for FTC to consider a settlement. FTC has put a pause on its lawsuit against Thousand Oaks-based Amgens. Amgen and Horizon Therapeutics plc resolve FTC lawsuit, clearing path to close acquisition. Amgen has consistently stated to the FTC, the courts and the public that it has no reason, ability or intention to bundle Horizons TEPEZZA (teprotumumumab-trbw) or KRYSTEXXA (pegloticase injection) with its products. Federal Trade Commission drops lawsuit to block drugmaker Amgens $28 billion deal to acquire Horizon Therapeutics. FTC said settlement would prevent “potential competitive harm. Amgen Associate Manufacturing in Holly Springs, North Carolina. Be part of Amgens newest and most advanced drug substance manufacturing plant. FTC was concerned that Amgen would leverage its drugs to secure favorable insurance coverage terms for Horizons thyroid eye disease treatment Tepezza and gout drug Krystexxa. Under the settlement, Amgen is prohibited from bundling any of its products with those drugs. Amgen-Horizon Therapeutics $28B acquisition: Federal Trade Commission Gives Green Signal. FTC settles with Amgen over $27.8B takeover of Horizon Therapeutic. FTC had argued in its suit that it would entrench Horizons monopoly on the drugs. Report: FTC Temporarily Suspends Challenge to $27.8B Amgen-Horizon Merger. Delay to allow agency to consider other ways of solving the issue.

Stock Profile

"Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California."

Keywords

The game is changing. There is a new strategy to evaluate Amgen fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Amgen are: Amgen, FTC, Horizon, Therapeutics, lawsuit, drug, product, and the most common words in the summary are: amgen, horizon, job, ftc, news, company, drug, . One of the sentences in the summary was: Federal Trade Commission (FTC) has allowed Amgen to continue its $27.8 billion acquisition of Horizon Therapeutics. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #amgen #horizon #job #ftc #news #company #drug.